Paul Delmar

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

Eric Van Cutsem, Sanne de Haas, Yoon‐Koo Kang et al. · Journal of Clinical Oncology · 2012 · 482 citations

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

Stephen Salloway, Martin R. Farlow, Eric McDade et al. · Nature Medicine · 2021 · 349 citations · Full text

Neurodegenerative Diseases, Neurobiology Of Disease, Alzheimer's Disease +9

Two Phase 3 Trials of Gantenerumab in Early Alzheimer’s Disease

Randall J. Bateman, Janice Smith, Michael Donohue et al. · New England Journal of Medicine · 2023 · 239 citations · Full text

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis

Gregory Klein, Paul Delmar, Nicola Voyle et al. · Alzheimer s Research & Therapy · 2019 · 200 citations · Full text

Functional validation of a genetic locus in the VEGFR-1 tyrosine kinase (TK) domain as a predictive marker for bevacizumab

Bart Claes, Paul Delmar, Betül T. Yesilyurt et al. · ePrints Soton (University of Southampton) · 2012 · 189 citations · Full text